Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Murtuza Bahrainwala

Internal Medicine Forsyth, IL Medical Doctor

NPI 1871590679 CMS profile 40118

509 Lucas Ln, Forsyth, IL 62535

Open in the dashboard

General payments

$5,421

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Murtuza Bahrainwala of Forsyth, IL is reported in the CMS Open Payments database as having received $5,421 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,098 48
2024 General $1,314 46
2023 General $1,146 75
2022 General $807 49
2021 General $582 31
2020 General $78 4
2019 General $396 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Murtuza Bahrainwala
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Murtuza Bahrainwala were reported at $1,098. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Murtuza Bahrainwala Internal Medicine median Middle half National median
2019 $396 $159 $48–$570 $163
2020 $78 $119 $33–$402 $114
2021 $582 $135 $37–$521 $132
2022 $807 $141 $42–$496 $149
2023 $1,146 $149 $45–$519 $160
2024 $1,314 $154 $47–$537 $164
2025 $1,098 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,125 40 payments
  2. AbbVie, Inc. $794 64 payments
  3. Lilly USA, LLC $654 40 payments
  4. Novo Nordisk Inc $543 39 payments
  5. Impulse Dynamics (USA) Inc. $339 3 payments
  6. Amgen Inc. $297 18 payments
  7. Novartis Pharmaceuticals Corporation $187 11 payments
  8. Amarin Pharma Inc. $177 9 payments
  9. Sanofi-Aventis U.S. LLC $150 1 payment
  10. Exact Sciences Corporation $130 6 payments
  11. Other $1,026 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,247 282 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
  3. Education $24 3 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $556 16 payments
  2. FARXIGA $485 18 payments
  3. AIRSUPRA $461 11 payments
  4. QULIPTA $438 28 payments
  5. Ozempic $432 30 payments
  6. UBRELVY $353 34 payments
  7. RYBELSUS $349 19 payments
  8. MOUNJARO $334 21 payments
  9. TRULICITY $316 20 payments
  10. JARDIANCE $308 18 payments
  11. Other $3,229 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

7,505

Median for Internal Medicine: 777

Drug cost

$896,630

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 65 $120,816
Jardiance Empagliflozin Brand 90 $115,648
Farxiga Dapagliflozin Propanediol Brand 101 $113,285
Mounjaro Tirzepatide Brand 78 $87,475
Trulicity Dulaglutide Brand 40 $72,402
Vascepa Icosapent Ethyl Brand 97 $71,167
Prolia Denosumab Brand 21 $37,457
Myrbetriq Mirabegron Brand 27 $23,774
Eliquis Apixaban Brand 28 $23,644
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $22,429

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$91,919

Of which drugs: $6,026

Medicare patients

220

Average age 74

Services billed

1,232

122 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 49%
Diabetes 47%
Arthritis 47%
Ischemic heart disease 39%
COPD 26%
Depression 25%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 50 50 $3,981

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $258
$258 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $198
$198 16 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $75
$75 101 —
Ozempic
  • Novo Nordisk Inc $66
$66 65 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
  • Lilly USA, LLC $24
$60 90 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record